The present invention provides a 1,4-disubstituted imidazole derivative of formula (1) wherein ring Q.sup.1 is optionally-substituted C.sub.6-10 aryl group, etc.; R.sup.1 and R.sup.2 are independently hydrogen atom, etc.; W.sup.1 is optionally-substituted C.sub.1-4 alkylene group; W.sup.2 is NR.sup.3aC(O) wherein R.sup.3a is hydrogen atom or C.sub.1-6alkyl group, etc.; ring Q.sup.2 is 5- to 10-membered heteroaryl group, etc.; W.sup.3 is optionally-substituted C.sub.1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R.sup.4 is independently halogen atom, optionally-substituted C.sub.1-6 alkyl group, etc.; R.sup.5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.

##STR00001##

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1) wherein ring Q.sup.1 is optionally-substituted C.sub.6-10 aryl group, etc.; R.sup.1 and R.sup.2 are independently hydrogen atom, etc.; W.sup.1 is optionally-substituted C.sub.1-4 alkylene group; W.sup.2 is NR.sup.3aC(O) wherein R.sup.3a is hydrogen atom or C.sub.1-6alkyl group, etc.; ring Q.sup.2 is 5- to 10-membered heteroaryl group, etc.; W.sup.3 is optionally-substituted C.sub.1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R.sup.4 is independently halogen atom, optionally-substituted C.sub.1-6 alkyl group, etc.; R.sup.5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent.

##STR00001##

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

The present invention relates to a novel compound showing leukotriene B4 receptor 2 (BLT2) inhibitory activity and a pharmaceutical composition, for preventing or treating inflammatory diseases, having same as an active ingredient. The inventors identified a novel compound containing BTL2 inhibitory activity, and experimentally confirmed that the present novel compound had an excellent effect on the enhancement of the cancer cell death, on the inhibition of the metastasis and chemotactic mobility, and on the anti-asthma activity. Therefore, the present novel compound can be used as a very effective pharmaceutical component for treating the inflammatory-related diseases.

Provided are a class of alkylphenol compounds and a preparation method therefor. Specifically provided are a new alkyl polyphenol compound as represented by chemical formula I, and a preparation method therefor and the use thereof in the treatment of metabolic syndrome.

##STR00001##

Provided are a class of alkylphenol compounds and a preparation method therefor. Specifically provided are a new alkyl polyphenol compound as represented by chemical formula I, and a preparation method therefor and the use thereof in the treatment of metabolic syndrome.

##STR00001##

Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.

Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.

The invention provides compounds having activity as bacterial RNA polymerase inhibitors and antibacterial agents, as well as compositions comprising the compounds and methods for their use. Specifically, phenylalanineamide and tyrosinamide compounds are disclosed that have inhibitory activity toward mycobacterium tuberculosis RNA polymerase. Use of these compounds in the treatment or prevention of M. tuberculosis infections in a mammal, is disclosed.